Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Harrington

Showing results (121-130 of 197) with videos related to

Pageof 20
Sort By:
Journal for Immunotherapy of Cancer|June 9, 2021
On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapyPablo Nenclares, Lucinda Gunn, Heba Soliman, et al.
Clinical and Translational Radiation Oncology|February 6, 2018
Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapyJamie Dean, Kee Wong, Hiram Gay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancerMartijn P Lolkema, Hendrik-Tobias Arkenau, Kevin Harrington, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2013
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapseNicolas Boisgerault, Timothy Kottke, Jose Pulido, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirusJian Qiao, Hongxun Wang, Timothy Kottke, et al.
Nature Medicine|June 21, 2011
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsTimothy Kottke, Fiona Errington, Jose Pulido, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.
Nature Medicine|December 11, 2007
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapyJian Qiao, Timothy Kottke, Candice Willmon, et al.
Future Oncology (London, England)|January 30, 2026
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCCLillian L Siu, Barbara Burtness, Kevin Harrington, et al.
Science Advances|June 5, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activityOlivia Liseth, Elizabeth Appleton, Benjamin Kendall, et al.
Pageof 20

Showing results (121-130 of 197) with videos related to

Sort By:
Pageof 20
Journal for Immunotherapy of Cancer|June 9, 2021
On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapyPablo Nenclares, Lucinda Gunn, Heba Soliman, et al.
Clinical and Translational Radiation Oncology|February 6, 2018
Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapyJamie Dean, Kee Wong, Hiram Gay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancerMartijn P Lolkema, Hendrik-Tobias Arkenau, Kevin Harrington, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2013
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapseNicolas Boisgerault, Timothy Kottke, Jose Pulido, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirusJian Qiao, Hongxun Wang, Timothy Kottke, et al.
Nature Medicine|June 21, 2011
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsTimothy Kottke, Fiona Errington, Jose Pulido, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.
Nature Medicine|December 11, 2007
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapyJian Qiao, Timothy Kottke, Candice Willmon, et al.
Future Oncology (London, England)|January 30, 2026
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCCLillian L Siu, Barbara Burtness, Kevin Harrington, et al.
Science Advances|June 5, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activityOlivia Liseth, Elizabeth Appleton, Benjamin Kendall, et al.
Pageof 20